This regimen, which is currently an established first‐line treatment option for patients with R/M SCCHN, is composed of ≤6 cycles of a platinum‐based chemotherapy (cisplatin/carboplatin +5‐fluorouracil [5‐FU]) with the anti‐epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab, followed by maintenance cetuximab therapy until progressive disease (PD).2 The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.